Trans-, cis-, and dihydro-resveratrol: A comparative study

Chemistry Central Journal

Volumn 5, Issue 1, 2011, Pages

  Anisimova, Natalia Y U ^a   Kiselevsky, Mikhail V ^a   Sosnov, Andrey V ^b   Sadovnikov, Sergey V ^c   Stankov, Ivan N ^c   Gakh, Andrei A ^d  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^c Chemical Diversity Research Institute   (Russian Federation)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83655211766     PISSN: None     EISSN: 1752153X     Source Type: Journal    
DOI: 10.1186/1752-153X-5-88     Document Type: Article

References (30)

1. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526. 10.1016/0140-6736(92)91277-F, 1351198.
2. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, Green J. Moderate Alcohol Intake and Cancer Incidence in Women. J Natl Cancer Inst 2009, 101:296-305. 10.1093/jnci/djn514, 19244173.
3. Li Y, Baer D, Friedman GD, Udaltsova N, Shim V, Klatsky AL. Wine, liquor, beer and risk of breast cancer in a large population. Eur J Cancer 2009, 45:843-850. 10.1016/j.ejca.2008.11.001, 19095438.
4. Newcomb PA, Nichols HB, Beasley JM, Egan K, Titus-Ernstoff L, Hampton JM, Trentham-Dietz A. No Difference Between Red Wine or White Wine Consumption and Breast Cancer Risk. Cancer Epidem Biomar 2009, 18:1007-1010.
5. Schoonen WM, Salinas CA, Kiemeney LAL, Stanford JL. Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 2005, 113:133-140. 10.1002/ijc.20528, 15386436.
6. Gakh AA, Anisimova NY, Kiselevsky MV, Sadovnikov SV, Stankov IN, Yudin MV, Rufanov KA, Krasavin MY, Sosnov AV. Dihydro-resveratrol--A potent dietary polyphenol. Bioorg Med Chem Lett 2010, 20:6149-6151. 10.1016/j.bmcl.2010.08.002, 20813524.
7. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High Absorption but Very Low Bioavailability of Oral Resveratrol in Humans. Drug Metab Dispos 2004, 32:1377-1382. 10.1124/dmd.104.000885, 15333514.
8. Cardile V, Lombardo L, Spatafora C, Tringali C. Chemo-enzymatic synthesis and cell-growth inhibition activity of resveratrol analogues. Bioorg Chem 2005, 33:22-33. 10.1016/j.bioorg.2004.08.003, 15668180.
9. Hsieh TC, Wu JM. Differential Effects on Growth, Cell Cycle Arrest, and Induction of Apoptosis by Resveratrol in Human Prostate Cancer Cell Lines. Exp Cell Res 1999, 249:109-115. 10.1006/excr.1999.4471, 10328958.
10. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, Casto ML, Vidali G, Castagnetta L. Estradiol Inhibits Growth of Hormone-nonresponsive PC3 Human Prostate Cancer Cells. Cancer Res 1994, 54:1190-1193.
11. Lau KM, LaSpina M, Long J, Ho SM. Expression of Estrogen Receptor (ER)-α and ER-β in Normal and Malignant Prostatic Epithelial Cells: Regulation by Methylation and Involvement in Growth Regulation. Cancer Res 2000, 60:3175-3182.
12. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73:233-244. 10.1016/j.steroids.2007.10.013, 2262439, 18093629.
13. Mak P, Leung YK, Tang WY, Harwood C, Ho SM. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 2006, 8:896-904. 10.1593/neo.06538, 1716010, 17132221.
14. Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB, Macdonald RS. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 2004, 49:200-208. 10.1207/s15327914nc4902_12, 15489213.
15. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms Involved in Resveratrol-Induced Apoptosis and Cell Cycle Arrest in Prostate Cancer-Derived Cell Lines. J Androl 2007, 28:282-293.
16. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, Oliveri G, Calabrò M, Carruba G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 1995, 136:2309-2319. 10.1210/en.136.5.2309, 7536668.
17. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP. Estrogen receptor-β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFα mediated. P Natl Acad Sci USA 2010, 107:3123-3128.
18. Zhu Y-S. Molecular Basis of Steroid Action in the Prostate. Cellscience 2005, 1:27-55. 1564164, 16971966.
19. El Touny LH, Banerjee PP. Identification of a Biphasic Role for Genistein in the Regulation of Prostate Cancer Growth and Metastasis. Cancer Res 2009, 69:3695-3703. 10.1158/0008-5472.CAN-08-2958, 2669842, 19351854.
20. Adlercreutz H, Mazur W, Bartels P, Elomaa VV, Watanabe S, Wähälä K, Landström M, Lundin E, Bergh A, Damber JE, Åman P, Widmark A, Johansson A, Zhang JX, Hallmans G. Phytoestrogens and Prostate Disease. J Nutr 2000, 130:658S-659S.
21. Adlercreutz H. Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 1995, 103:103-112. 1518828, 8635434.
22. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. P Natl Acad Sci USA 1997, 94:14138-14143.
23. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol Acts as a Mixed Agonist/Antagonist for Estrogen Receptors α and β. Endocrinology 2000, 141:3657-3667. 10.1210/en.141.10.3657, 11014220.
24. Basly J-P, Marre-Fournier F, Le Bail J-C, Habrioux G, Chulia AJ. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 2000, 66:769-777. 10.1016/S0024-3205(99)00650-5, 10698352.
25. Benitez DA, Pozo-Guisado E, Clementi M, Castellon E, Fernandez-Salguero PM. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 2007, 96:1595-1604. 10.1038/sj.bjc.6603755, 2359939, 17486135.
26. Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward JE, Jameson JL, Jordan VC. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER β. Int J Cancer 2003, 104:587-596. 10.1002/ijc.10992, 12594813.
27. vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, Dhar MD, Ganjam VK, Parmigiani S, Welshons WV. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. P Natl Acad Sci USA 1997, 94:2056-2061.
28. Li L, Andersen ME, Heber S, Zhang Q. Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. J Mol Endocrinol 2007, 38:569-585. 10.1677/JME-07-0003, 17496158.
29. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E, Vannini V. Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Effects of Resveratrol. J Biol Chem 2001, 276:22586-22594. 10.1074/jbc.M101846200, 11316812.
30. Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G. Effects of resveratrol on human immune cell function. Life Sci 2001, 70:81-96. 10.1016/S0024-3205(01)01367-4, 11764009.